Related Experiment Video
Updated: May 10, 2025
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
9.9K
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services
Tark J Patel1, Eman Wehbe1, Stephen Hughes1
1School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
The Pharmacogenomics Journal
|April 25, 2025
Summary
Pharmacogenomic testing for CYP2C19 improves clopidogrel use and reduces heart attack risk. Understanding testing service requirements is key for widespread implementation of this personalized medicine approach.
Area of Science:
- Clinical Pharmacology
- Genetics
- Cardiology
Background:
- CYP2C19 pharmacogenomic testing personalizes clopidogrel therapy, reducing secondary myocardial infarction risk.
- Routine testing is uncommon due to poorly understood service requirements and processes.
Purpose of the Study:
- To explore literature on CYP2C19 testing services for clopidogrel.
- Identify commonalities in existing services to inform future design and delivery.
Main Methods:
- Scoping review of 37 eligible studies.
- Analysis of services across hospital and community settings.
Main Results:
- Key delivery elements include multidisciplinary teams (physicians, pharmacists), pre-implementation training, and electronic result communication.
- Integration of results into clinical decision support systems enhances practical application.
Conclusions:
- Identifying key requirements and processes can guide institutions in designing and delivering CYP2C19 testing services.
- Optimized service delivery can improve clopidogrel therapy guidance.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K